Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.33 USD | +0.87% | -4.51% | -44.66% |
04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
04-25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
Business Summary
Number of employees: 977
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Transformative Medicines Based on Messenger Ribonucleic Acid
100.0
%
| 71 | 100.0 % | 58 | 100.0 % | -17.98% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Belgium
87.7
%
| 65 | 92.4 % | 51 | 87.7 % | -22.14% |
Switzerland
10.1
%
| 4 | 5.0 % | 6 | 10.1 % | +65.60% |
Netherlands
2.2
%
| 2 | 2.7 % | 1 | 2.2 % | -31.10% |
Others
0.0
%
| - | - | 0 | 0.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 23-03-27 | |
Pierre Kemula
DFI | Director of Finance/CFO | 50 | 16-10-31 |
Malte Greune
COO | Chief Operating Officer | 59 | 21-06-30 |
Sarah Fakih
IRC | Investor Relations Contact | - | - |
Myriam Mendila
PRN | Corporate Officer/Principal | 58 | 23-01-31 |
Patrick Baumhof
PRN | Corporate Officer/Principal | - | - |
Antony Blanc
PRN | Corporate Officer/Principal | 57 | 20-12-03 |
Ulrike Gnad-Vogt
PRN | Corporate Officer/Principal | - | 10-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Craig Tooman
BRD | Director/Board Member | 58 | 19-05-31 |
Michael Brosnan
BRD | Director/Board Member | 69 | 23-06-18 |
Director/Board Member | 67 | 22-06-21 | |
Chairman | 73 | 15-07-31 | |
Mathias Hothum
BRD | Director/Board Member | 58 | 15-07-31 |
Director/Board Member | 61 | 22-06-21 | |
Viola Bronsema
BRD | Director/Board Member | 61 | 20-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 223,923,708 | 122,200,574 ( 54.57 %) | 0 | 54.57 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.66% | 522M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CVAC Stock
- Company CureVac N.V.